X

Trial Profile

FOLLOW-UP STUDY OF ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Jan 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary)
Indications Urogenital cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Chugai Pharmaceutical

Most Recent Events

22 Dec 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2024.
30 Oct 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
14 Jun 2018 Status changed from suspended to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com